Therefore, wild-type KRAS might serve as a tumour-suppressor gene in the presence of mutant KRAS (Luo et al., 2014; To et al., 2013; Zhang et al., 2001; Zhongqiu Hartman et al., 2012). Here, KRAS is linked to neoplasm.